Y08284

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Y08284 

Y08284 是一种高效、选择性、口服活性 CBP bromodomain 抑制剂，IC50 为 4.21 nM。Y08284 抑制前列腺癌细胞系 LNCaP、C4-2B 和 22Rv1 的增殖。抗肿瘤活性。

Y08284

Y08284 Chemical Structure

CAS No. : 2688745-47-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity[1].

体内研究
(In Vivo)

Y08284 demonstrates favorable cell permeability and good pharmacokinetic properties, with oral bioavailability of 25.9%[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

476.50

Formula

C26H25FN4O4
CAS 号

2688745-47-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Xiang Q, et al. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2022;65(1):785-810.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务